NCT06394661View on ClinicalTrials.gov

Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

109

Participants

Timeline

Start Date

April 28, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2028

Conditions

Breast Cancer

Interventions

DRUG

Serplulimab+NabPE

Serplulimab plus neoadjuvant nab-PE: Epirubicin 75mg/m2 ivgtt on Day 1+Albumin Paclitaxel 260mg/m2 ivgtt on Day 1+Serplulimab 4.5mg/Kg ivgtt on Day 3）

Trial Locations (1)

450008

Henan cacer hospital, Henan

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV

NCT06394661 - Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer | Biotech Hunter | Biotech Hunter